Compare Prologis Inc (PLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs BIO-TECHNE Corp — how do they compare? Prologis Inc trades at $128.94 (market cap $120.98B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Prologis Inc is far larger — about 10.6× BIO-TECHNE Corp's market cap, and Prologis Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and BIO-TECHNE Corp for 63 Days on average.
| PLD | TECH | |
|---|---|---|
Market Cap | $120.98B | $11.37B |
Volume | 3,604,776 | 3,153,511 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $72.61 |
52-Week Low | $111.23 | $43.31 |
Typical Hold Time | 102 Days | 63 Days |
Enterprise Value | $155.72B | $11.40B |
Dividend Yield | 3.36% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $127.3, down 1.07% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and three consecutive quarterly EPS beats. The stock is supported by robust cash flow from operations of $5.01B in 2025 and positive leasing momentum highlighted by management. Recent news emphasizes growth from warehouse and data center demand, though technical indicators show selling pressure with key support at $126.
The outlook is mixed: analyst consensus is bullish with a $155.15 price target (59.52% buy ratings), but rising debt-to-asset ratios and bearish moving averages pose risks. Upside hinges on continued execution in logistics real estate, while macroeconomic sensitivity and valuation premiums require monitoring for sustained shareholder returns.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
